Zoliflodacin: An oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrhoeae, including multi-drug resistant isolates.

The CDC and World Health Organization have issued a list of priority pathogens for which there are dwindling therapeutic options, including antibiotic-resistant N. gonorrhoeae, for which novel, oral agents are urgently needed. Zoliflodacin, the first in a new class of antibacterial agents called the spiropyrimidinetriones, is being developed for the treatment of gonorrhea. It has a unique mode-of-inhibition against bacterial type II topoisomerases with binding sites in bacterial gyrase that are distinct from those of the fluoroquinolones. Zoliflodacin is bactericidal, with a low frequency of resistance and potent antibacterial activity against N. gonorrhoeae, including multi-drug resistant strains (MICs ranging from